Core Insights - Henry Schein has outlined its roadmap for 2026, focusing on improving profitability and expanding high-margin businesses at the J.P. Morgan Healthcare Conference [1] Company Strategy - The company is a leading provider of medical products, equipment, and services in alternative care and home care markets, emphasizing shifts in healthcare delivery while tightening operational costs [2] - Henry Schein aims to achieve more than $200 million in operating income improvements over the next few years through lower costs and higher gross margins [5] - The long-term strategy, BOLD +1, targets 50% of non-GAAP operating income from high-growth, high-margin businesses by the end of 2027, with an additional 10% from corporate brands [6] Market Trends - Patient traffic is rising in the medical market, with a shift towards outpatient care and increased demand for chronic disease management and preventative healthcare, leading to expected mid-single digit growth in the medical sector [3] Financial Performance - The company reports strong cash flow, with a non-GAAP earnings per diluted share compound annual growth rate of 6.2% [4] Management Changes - A significant announcement at the J.P. Morgan Healthcare Conference was the change in management, with Fred Lowery set to become CEO effective March 2, 2026 [7]